Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Japan Large Molecule Drug Substance CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service
  • 5.2.1.1 Contract Manufacturing
  • 5.2.1.2. Contract Development
  • 5.2.2. By Source
  • 5.2.2.1 Mammalian
  • 5.2.2.2 Microbial, Other
  • 5.2.3. By End User
  • 5.2.3.1 Biotech Companies
  • 5.2.3.2 CRO
  • 5.2.3.3 Others
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Hokkaido Large Molecule Drug Substance CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Source
  • 6.2.3. By End User

7. Tohoku Large Molecule Drug Substance CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Source
  • 7.2.3. By End User

8. Kanto Large Molecule Drug Substance CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Source
  • 8.2.3. By End User

9. Chubu Large Molecule Drug Substance CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Source
  • 9.2.3. By End User

10. Kansai Large Molecule Drug Substance CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Source
  • 10.2.3. By End User

11. Chugoku Large Molecule Drug Substance CDMO Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Service
  • 11.2.2. By Source
  • 11.2.3. By End User

12. Shikoku Large Molecule Drug Substance CDMO Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Service
  • 12.2.2. By Source
  • 12.2.3. By End User

13. Kyushu Large Molecule Drug Substance CDMO Market Outlook

• 13.1. Market Size & Forecast
  • 13.1.1. By Value
• 13.2. Market Share & Forecast
  • 13.2.1. By Service
  • 13.2.2. By Source
  • 13.2.3. By End User

14. Market Dynamics

• 14.1. Drivers
• 14.2. Challenges

15. Market Trends & Developments

• 15.1. Merger & Acquisition (If Any)
• 15.2. Product Launches (If Any)
• 15.3. Recent Developments

16. Japan Large Molecule Drug Substance CDMO Market: SWOT Analysis

17. Porter's Five Forces Analysis

• 17.1. Competition in the Industry
• 17.2. Potential of New Entrants
• 17.3. Power of Suppliers
• 17.4. Power of Customers
• 17.5. Threat of Substitute Products

18. Competitive Landscape

• 18.1. Chiyoda Corporation
  • 18.1.1. Business Overview
  • 18.1.2. Company Snapshot
  • 18.1.3. Products & Services
  • 18.1.4. Financials (As Reported)
  • 18.1.5. Recent Developments
  • 18.1.6. Key Personnel Details
  • 18.1.7. SWOT Analysis
• 18.2. Sumitomo Chemical Co., Ltd.
• 18.3. Otsuka Chemical Co., Ltd.
• 18.4. Bushu Pharmaceuticals
• 18.5. Terumo Corporation
• 18.6. Nipro Corporation
• 18.7. Zonnebodo Pharmaceutical Co., Ltd.
• 18.8. PharmaBio Corporation
• 18.9. ROHTO Pharmaceutical Co., Ltd.
• 18.10. Asahi Kasei Pharma Corporation

19. Strategic Recommendations

20. About Us & Disclaimer